International Transfer Pricing in the Ethical Pharmaceutical Industry

International Transfer Pricing in the Ethical Pharmaceutical Industry
Book
Karl Wündisch
FormatOnline
EUR
219
| USD
279
(VAT excl.)

This book presents a perspective of the particular circumstances that the ethical pharmaceutical industry must take into account regarding transfer pricing.

Why this book?

This report was originally a study commissioned by a number of leading pharmaceutical companies into the transfer pricing of ethical pharmaceutical products, i.e. those products whose safety, efficacy and quality have been proven by state-of-the-art scientific methods. Since its original publication, significant developments have occurred in both the industry and with respect to transfer pricing. In light of these developments, the updated edition presents a current perspective of the particular circumstances that the ethical pharmaceutical industry must take into account regarding transfer pricing.

The report is intended to stimulate discussion of these issues at all levels, i.e. amongst national and supranational authorities, non-governmental organizations, the academic world, transfer pricing practitioners advising governments and industry, and experts and executives in the ethical pharmaceutical industry itself.

The text is fully supported by examples, statistics and charts to demonstrate and, where possible, visualise the particulars of the ethical pharmaceutical industry in relation to its transfer pricing. Background information and pertinent references ensure that the report is accessible also to those previously unfamiliar with the industry.

International Transfer Pricing in the Ethical Pharmaceutical Industry

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Part 2: Characteristics of the Ethical Pharmaceutical Industry

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Part 3: How Market Prices are Determined

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Part 4: Transfer Pricing in the Ethical Pharmaceutical Industry

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Part 5: Discussion of the General Approach of Tax Authorities

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Part 6: Testing and Defending Transfer Prices on the Arm’s Length Basis

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Part 7: General Summary and Conclusions

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix A: The Research and Development Process

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix B: Cost of Developing a New Medicine

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix C: Time to Develop a New Medicine

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix E: Attribution of R&D Costs to Individual Products

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix G: Intellectual Property Rights and Licensing

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix H: US Transfer Pricing of Intangibles

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix J: Government Intervention

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix K: Mergers in the Industry

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix L: Low-Tax Areas: Special Tax Reliefs and Fiscal Incentives in Certain Countries

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix M: – Background Material

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix P: Shareholding in Affiliates

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix R: OECD Transfer Pricing Reports and Multinational Enterprises

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

Appendix U: Methods of Determining Arm’s Length Prices

DOI: https://doi.org/10.59403/25rvwwv
Go to Tax Research Platform

The second revised and enlarged edition has been updated by Karl Wündisch, an industry executive and transfer pricing expert. Mr Wündisch currently holds worldwide responsibility for the transfer pricing of an ethical pharmaceutical group.